KYMR · Kymera Therapeutics, Inc. · Webcasts, Transcripts & Audio
$115.31
-4.08 (-3.42%)
At close · Nov 20
Return incl. dividend (before tax)
Q3 2026 earnings call transcript
Market Cap
$9.84B
Shares
85.37M
Volume · Nov 20
1.28M
Avg daily vol (3M)
847.26K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Kymera Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Kymera Therapeutics, Inc. (KYMR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-29
Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript
Revenue
$0
▼ 100% YoY Diluted EPS
$-1.32
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-15
Kymera Therapeutics, Inc. (KYMR) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-14
Kymera Therapeutics, Inc. (KYMR) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Kymera Therapeutics, Inc. (KYMR) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
Confident tone
KT-621 Asthma and other type 2 indications
Financial strength and runway
Pediatric and label expansion strategy
Revenue
$65.00M
▲ 466.4% YoY Diluted EPS
$-0.62
Gross margin
0.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Kymera Therapeutics, Inc. (KYMR) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Kymera Therapeutics, Inc. (KYMR) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript
Revenue
$34.37M
▲ 55.5% YoY Diluted EPS
$-0.71
Gross margin
0.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-12
Kymera Therapeutics, Inc. (KYMR) March 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-26
Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript
Confident tone
KT-579 IRF5 Degrader for Lupus
KT-621 STAT6 Degrader in Atopic Dermatitis and Asthma
Enrollment Dynamics and Competition
Revenue
$2.87M*
▼ 61.2% YoY Gross margin
0.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Kymera Therapeutics, Inc. (KYMR) Q3 2025 Earnings Call Transcript
Confident tone
KT-621 STAT6 program
BroADen Phase Ib data readout
Asthma and pediatric opportunity
Revenue
$2.76M
▼ 26.1% YoY Diluted EPS
$-0.94
Gross margin
0.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Kymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call Transcript
Confident tone
KT-621 STAT6 program
Phase IIb dose selection and trial planning
Biomarker and clinical endpoint expectations
Revenue
$11.48M
▼ 55.3% YoY Diluted EPS
$-0.95
Gross margin
0.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call Transcript
Confident tone
IRAF5 program introduction
Immunology opportunity and market
Clinical execution and milestones
Revenue
$22.10M
▲ 114.8% YoY Diluted EPS
$-0.82
Gross margin
0.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript
Confident tone
STAT6 / KT-621 program
Clinical readout timing risks
TYK2 / KT-295 program
Revenue
$7.39M*
▼ 84.6% YoY Gross margin
0.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript
Confident tone
KT-621 STAT6 degrader Phase 1
TYK2 program progression
Partnership considerations for STAT6
Revenue
$3.74M
▼ 20.9% YoY Diluted EPS
$-0.82
Gross margin
0.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript
Confident tone
KT-621 / STAT6 program
KT-474 / IRAK4 program
Pipeline and platform
Revenue
$25.65M
▲ 55.3% YoY Diluted EPS
$-0.58
Gross margin
0.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript
Confident tone
IRAK4 / KT-474 program
STAT6 degrader KT-621
TYK2 degrader KT-294
Revenue
$10.29M
▲ 8.7% YoY Diluted EPS
$-0.69
Gross margin
0.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Kymera Therapeutics, Inc. (KYMR) Q4 2023 Earnings Call Transcript
Confident tone
STAT6 degrader (KT-621)
IRAK4 / KT-474 program with Sanofi
TYK2 degrader (KT-294)
Revenue
$47.88M*
▲ 196.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript
Revenue
$4.73M
▼ 50.5% YoY Diluted EPS
$-0.90
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Kymera Therapeutics, Inc. (KYMR) Q2 2023 Earnings Call Transcript
Revenue
$16.51M
▲ 43.4% YoY Diluted EPS
$-0.67
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Kymera Therapeutics, Inc. (KYMR) Q1 2023 Earnings Call Transcript
Revenue
$9.47M
▼ 1.6% YoY Diluted EPS
$-0.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-10
Kymera Therapeutics, Inc. (KYMR) Q4 2022 Earnings Call Transcript
Revenue
$16.14M*
▲ 5.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Kymera Therapeutics, Inc. (KYMR) Q3 2022 Earnings Call Transcript
Revenue
$9.55M
▼ 53% YoY Diluted EPS
$-0.79
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Kymera Therapeutics, Inc. (KYMR) Q2 2022 Earnings Call Transcript
Revenue
$11.51M
▼ 37.8% YoY Diluted EPS
$-0.78
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Kymera Therapeutics, Inc. (KYMR) Q1 2022 Earnings Call Transcript
Revenue
$9.62M
▼ 48.6% YoY Diluted EPS
$-0.71
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–25 of 25 webcasts
Key facts
CIK
1815442
CUSIP
501575104
13F (30d)
320 filings
293 filers
Visit website
Investor relations